Glycogen storage diseases of muscle

Current Opinion in Neurology

Volumn 11, Issue 5, 1998, Pages 477-484

  DiMauro, Salvatore ^a   Bruno, Claudio ^a  

^a College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRANCHED CHAIN AMINO ACID; FRUCTOSE BISPHOSPHATE ALDOLASE; GLUCAN 1,4 ALPHA GLUCOSIDASE; GLYCOGEN; GLYCOGEN PHOSPHORYLASE; MYOGLOBIN; PHOSPHORYLASE KINASE; PYRIDOXINE; RECOMBINANT ENZYME;

ENZYME DEFICIENCY; ENZYME REPLACEMENT; EXERCISE; GENE MUTATION; GENE THERAPY; GLYCOGEN METABOLISM; GLYCOGEN STORAGE DISEASE; HEMOLYSIS; HUMAN; MUSCLE CRAMP; MUSCLE DISEASE; MUSCLE WEAKNESS; MYOGLOBINURIA; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN DIET; REVIEW;

ANIMALS; DISEASE MODELS, ANIMAL; GENE THERAPY; GLYCOGEN STORAGE DISEASE; HUMANS; MUSCLES;

EID: 0031751198     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-199810000-00010     Document Type: Review

References (61)

1. DiMauro S, Servidei S, Tsujino S. Disorders of carbohydrate metabolism: glycogen storage diseases. In: The molecular and genetic basis of neurological disease. 2nd edn. Rosenberg RN, Prusiner SB, DiMauro S, Barchi RL (editors). Boston: Butterworth-Heinemann; 1997, pp. 1067-1097.
2. Chen YT, Burchell A. Glycogen storage diseases. In: The metabolic and molecular basis of inherited disease. Scriver CR, Beaudet AL, Sly WS, Valle D (editors). 7th edn. New York: McGraw-Hill, 1995, pp. 935-966.
3. Ausems MGEM, van Diggelen OP, Sinke RJ, Reuser AJJ, Wokke JHJ. Genotype of adult-onset glycogen storage disease type II in asymptomatic patients [abstract]. Neurology 1998; 50:A117.
4. de Jager AE, van der Vliet TM, van der Ree TC, Oosterink BJ, Loonen MC. Muscle computed tomography in adult-onset acid maltase deficiency. Muscle Nerve 1998; 21:398-400.
5. El-Schahawi M, Bruno C, Tsujino S, Sarrazin AM, Shanske S, LeRoux MG, DiMauro S. Sudden infant death syndrome (SIDS) in a family with myophosphorylase deficiency. Neuromusc Disord 1997; 7:81-83.
6. Bruno C, Bado M, Minetti C, Cordone G. Forearm semi-ischemic exercise test in pediatric patients. J Child Neurol 1998; 13:288-290.
7. Tsujino S, Shanske S, Carroll JE, Sabina RL, DiMauro S. Double trouble: combined myophosphorylase and AMP deaminase deficiency in a child homozygous for nonsense mutations at both loci. Neuromusc Disord 1995; 5: 263-266.
8. Bruno C, Minetti C, Shanske S, Morreale G, Bado M, Cordone G, DiMauro S: Combined defects of muscle phosphofructokinase and AMP deaminase in a child with myoglobinuria. Neurology 1998; 50:296-298.
9. Rubio JC, Martin MA, Bautista J, Campos Y, Segura D, Arenas J. Association of genetically proven deficiencies of myophosphorylase and AMP deaminase: a second case of 'double trouble'. Neuromusc Disord 1997; 7:387-389.
10. Morisaki T, Gross M, Morisaki H, Pongratz D, Zollner N, Holmes EW. Molecular basis of AMP deaminase deficiency in skeletal muscle. Proc Nat Acad Sci USA 1992; 89:6457-6461.
11. Heller SL, Kaiser KK, Planer GJ, Hagberg JM, Brooke MH. McArdle's disease with myoadenylate deaminase deficiency: observations in a combined enzyme deficiency. Neurology 1987; 37:1039-1042.
12. Sahin G, Güngör T, Rettwitz-Volk W, Schlote W, Shin YS, Podskarbi T, Sewell AC. Infantile muscle phosphorylase-b-kinase deficiency. A case report, Neuropediatrics 1998; 29:48-50.
13. Kreuder J, Borkhardt A, Repp R, Pekrun A, Gotische B, Gottschalk U, et al. Inherited metabolic myopathy and hemolysis due to a mutation in aldolase A. N Engl J Med 1996; 334:1100-1104.
14. Bijvoet AGA, van de Kamp EHM, Kroos MA, Ding JH, Yang BZ, Bakker CE, et al. Generalised glycogen storage and cardiomegaly in a knockout mouse model of Pompe disease. Hum Mol Genet 1998; 7:53-62. This is the first genetically engineered animal model of a glycogenosis. Homozygous knockout mice show virtually complete and generalized AMO. Although the clinical picture is less dramatic than in humans with Pompe disease, this model will be invaluable in clarifying pathogenetic mechanisms and in developing therapeutic approaches.
15. Angelos S, Valberg SJ, Smith BP, McQuarrie PS, Shanske S, Tsujino S. et al. Myophosphorylase deficiency associated with rhabdomyolysis and exercise intolerance in six related Charolais cattle. Muscle Nerve 1995; 18:736-740.
16. Tan P, Allen JG, Wilton SD, Akkari PA, Huxtable CR, Laing NG. A splice-site mutation causing ovine McArdle's disease. Neuromusc Disord 1997; 7:336-342. This is the second spontaneous animal model of myophosphorylase deficiency (McArdle disease). The ovine model, because of the smaller size of the animal, may be more convenient than the bovine model for therapeutic trials.
17. Tsujino S, Shanske S, Valberg SJ, Cardinet GH, Smith BS, DiMauro S. Cloning of bovine muscle glycogen phosphorylase cDNA and identification of a mutation in cattle with myophosphorylase deficiency, an animal model for McArdle's disease. Neuromusc Disord 1995; 6:19-26.
18. Giger U, Harvey JW, Yamaguchi RA, McNulty PK, Chiapella A, Beutler E. Inherited phosphofructokinase deficiency in dogs with hyperventilation-induced hemolysis: Increased in vitro and in vivo alkaline fragility of erythrocytes. Blood 1985; 65:345-351.
19. Smith BF, Stedman H, Rajpurohit Y, Henthorn PS, Wolfe JH, Patterson DF, Giger U. Molecular basis of canine muscle type phosphofructokinase deficiency. J Biol Chem 1998; 271:20070-20074.
20. +K -ATPase in McArdle disease. Neurology 1998; 50:37-40. This is an elegant demonstration that sodium-potassium ATPase pumps are decreased in muscle from McArdle disease patients, which provides a rational explanation for a number of previously puzzling empirical observations.
21. James JH, Fang C-H, Schrantz SJ, Hasselgren P-O, Paul RJ, Fischer JE. Linkage of aerobic glycolysis to sodium-potassium transport in rat skeletal muscle. J Clin Invest 1996; 98:2388-2397.
22. Ruff RL. Why do patients with McArdle's disease have decreased exercise capacity? Neurology 1998; 50:6-7.
23. Vissing J, Vissing SF, MacLean DA, Saltin B, Quistorff B, Haller RG, Sympathetic activation in exercise is not dependent on muscle acidosis. Direct evidence from studies in metabolic myopathies. J Clin Invest 1998; 101:1654-1660. This is another elegant example of clinical investigation 'exploiting' human metabolic diseases as 'experiments of nature' to answer vexing physiologic questions.
24. DiMauro S, Tsujino S. Nonlysosomal glycogenoses. In: Myology. 2nd edn. Engel AG, Franzini-Armstrong C (editors). New York: McGraw-Hiill, 1994: pp. 1554-1576.
25. Bresolin N, Miranda AF, Jacobson M, Lee JH, Capilupi T, DiMauro S. Phosphorylase isoenzymes of human brain. Neurochem Pathol 1983; 1:171-178.
26. Salvan AM, Vion-Dury J, Confort-Gouny S, Dano P, Cozzone PJ. Increased cerebral glycogen detected by localized 1H-magnetic resonance spectroscopy in a patient with suspected McArdle's disease. Eur Neurol 1997; 37:251-253. This is a provocative and unexpected observation. If confirmed, it raises the possibility that patients with McArdle disease may have more than a pure myopathy.
27. Beesley CE, Child AH, Yacoub MH. The identification of five novel mutations in the lysosomal acid alpha(1,4)glucosidase gene from patients with glycogen storage disease type II. Hum Mutat 1997; 11:413.
28. Huie ML, Tsujino S, Sklower Brooks S, Engel AG, Elias E, Bonthron DT, et al. Glycogen storage disease type II: identification of four novel missense mutations (D645N, G648S, R672W, R672Q) and two insertions/deletions in the acid alpha-glucosidase locus of patients of differing phenotype. Biochem Biophys Res Commun 1998; 244:921-927.
29. Kroos MA, Waitfield AE, Joose M, Winchester B, Reuser AJJ, MacDermot KD. A novel acid alpha-glucosidase mutation identified in a pakistani family with glycogen storage disease type II. J Inherit Metab Dis 1997; 20:556-558.
30. Hermans MM, van Leenen D, Kroos MA, Reuser AJ. Mutation detection in glycogen storage-disease type II by RT-PCR and automated sequencing. Biochem Biophys Res Commun 1997; 241:414-418.
31. Kroos MA, Van der Kraan M, Van Diggelen OP, Kleijer WJ, Reuser AJ. Two extremes of the clinical spectrum of glycogen storage disease type II in one family: a matter of genotype. Hum Mutat 1997, 9:17-22. A nice example of genotype-phenotype correlation in very differently affected members of the same family is presented.
32. Adams EM, Becker JA, Griffith L, Segal A, Plotz PH, Raben N. Glycogenosis type II: a juvenile-specific mutation with an unusual splicing pattern and a shared mutation in African Americans. Hum Mutat 1997; 10:128-134.
33. Hermans MM, Kroos MA, Smeitink JA, van der Ploeg AT, Kleijer WJ, Reuser AJ. Glycogen storage disease type II: genetic and biochemical analysis of novel mutations in infantile patients from Turkish ancestry. Hum Mutat 1998; 11:209-215.
34. Shen J, Bao Y, Liu H-M, Lee P, Leonard JV, Chen Y-T. Mutations in exon 3 of the glycogen debranching enzyme gene are associated with glycogen storage disease type III that is differentially expressed in liver and muscle. J Clin Invest 1996; 98:352-357.
35. Parvari R, Shen J, Hershkovitz E, Chen YT, Moses SW. Two new mutations in the 3′ coding region of the glycogen debranching enzyme in a glycogen storage disease type IIIa Ashkenazi Jewish patient. J Inher Metab Dis 1998; 21:141-148.
36. Comi GP, Hadjigeorgiou Y, Franceschina L, Bordoni A, Salani S, Nesti S, et al. Molecular analysis of glycogen debrancher enzyme gene in glycogen storage disease type IIIa patients [abstract]. Clin Neuropathol 1998; 17:151.
37. Lossos A, Barash V, Soffer D, Argov Z, Gomori M, Ben-Nariah Z, et al. Hereditary branching enzyme dysfunction in adult polyglucosan body disease: possible metabolic cause in two patients. Ann Neurol 1991; 30:655-662.
38. Bruno C, Servidei S, Shanske S, Karpati G, Carpenter S, McKee D, et al. Glycogen branching enzyme deficiency in adult polyglucosan body disease. Ann Neurol 1993; 33:88-93.
39. Lossos A, Meiner Z, Barash V, Soffer D, Abramsky O, Argov Z, Meiner V. Adult polyglucosan body disease caused by the Tyr329Ser mutation in the glycogen branching enzyme gene in Ashkenazi Jew [abstract]. Ann Neurol 1998, 42: 987. This is the first molecular defect in APBD, and one of the first mutations in the branching enzyme gene.
40. Kubisch C, Wicklein EM, Jentsch TJ. Molecular diagnosis of McArdle disease: revised genomic structure of the myophosphorylase gene and identification of a novel mutation. Hum Mutat 1998; 12:27-32. This revision of the genomic structure of the myophosphorylase gene simplifies the detection of mutations and will help document the already striking genetic heterogeneity of McArdle disease.
41. Tsujino S, Shanske S, DiMauro S. Molecular genetic heterogeneity of myophosphorylase deficiency (McArdle's disease). N Engl J Med 1993; 329:241-245.
42. Vorgerd M, Kubisch C, Burwinkel B, Reichmann H, Mortier W, Tettenborn B, et al. Mutation analysis in myophosphorylase deficiency (McdArdle's disease). Ann Neurol 1998; 43: 326-331.
43. Iyengar S, Kalinsky H, Weiss S, Korotishevsky M, Sadeh M, Zhao Y, et al. Homozygosity by descent for a rare mutation in the myophosphorylase gene associated with variable phenotype in a Druze family with McArdle disease. J. Med Genet 1997; 34:391-394.
44. Bartram C, Edwards RHT, Clague J, Beynon RJ. McArdle's disease: a nonsense mutation in exon 1 of the muscle glycogen phosphorylase gene explains some but not all cases. Hum Mol Genet 1993, 2:1291-1293.
45. Martinuzzi A, Tsujino S, Vergani L, Schievano G, Cadaldini M, Bartoloni L, et al. Molecular characterization of myophosphorylase deficiency in a group of patients from Northern Italy. J Neurol Sci 1996; 137:14-19.
46. Andreu AL, Bruno C, Gamez J, Shanske S, Cervera C, Navarro C, et al. Molecular genetic analysis of McArdle's disease in Spanish patients. Neurology 1998; 51:260-262.
47. Gospe SM, El-Schahawi M, Shanske S, Bruno C, DiMauro S, Hoye E, Walsh DA, Gorin FA. Asymptomatic patient with myophosphorylase deficiency, high CK, and the L.396P mutation [abstract]. Neurology 1997, 48:A320.
48. Wehner M, Clemens PR, Engel AG, Kilimann MW. Human muscle glycogenosis due to phosphorylase kinase deficiency associated with a nonsense mutation in the muscle isoform of the alpha subunit. Hum Mol Genet 1994; 3:1983-1987.
49. Bruno C, Manfredi G, Andreu AL, Shanske S, Ilse W, DiMauro S. A novel mutation in a patient with muscle phosphorylase b kinase deficiency. Biochem Biophys Res Comm 1998; (in press).
50. Sugie H, Sugie Y, Nishida M, Ito M, Tsurui S, Suzuki M, et al. Recurrent myoglobinuria in a child with mental retardation: phosphoglycerate kinase deficiency. J Child Neurol 1989; 4:95-99.
51. Sugie H, Sugie Y, Ito M, Fukuda T. A novel missense mutation (837T →C) in the phosphoglycerate kinase gene of a patient with a myopathic form of phosphoglycerate kinase deficiency. J Child Neurol 1998; 13:95-97.
52. Pauly DF, Johns DC, Matelis LA, Lawrence JH, Byrne BJ, Kessler PD. Complete correction of acid alpha-glucosidase deficiency in Pompe disease fibroblasts in vitro, and lysosomally targeted expression in neonatal rat cardiac and skeletal muscle. Gene Ther 1998; 473-480. A promising approach to gene therapy of the devastating infantile form of AMD (Pompe disease) is presented.
53. Kikuchi T, Yang HW, Pennybacker M, Ichihara N, Mitzutani M, Van Hove JLK, Chen YT. Clinical and metabolic correction of Pompe disease by enzyme therapy in acid maltase-deficient quail. J Clin Invest 1998; 101:827-833. An even more promising enzyme replacement therapy approach is presented which has shown clinical improvement in a spontaneous avian animal model of AMD.
54. Yang HW, Kikuchi T, Hagiwara Y, Mizutani M, Chen YT, Van Hoive JL. Recombinant human acid alpha-glucosidase corrects acid alpha-glucosidase-deficient human fibroblasts, quail fibroblasts, and quail myoblasts, Pediatr Res 1998; 43:374-380.
55. Bodamer OAF, Leonard JV, Halliday D. Dietary treatment in late-onset acid maltase deficiency. Eur J Pediatr 1997; 156 (Suppl 1):S39-S42.
56. Haller RG, MacLean D, Vissing S, Vissing J. Oral branched-chain amino acids do not improve exercise capacity in McArdle's disease. Neurology 1998; (in press).
57. Haller RG, Wyrick P, Cavender D, Wall A, Vissing J. Aerobic conditioning: an effective therapy in McArdle's disease. Neurology 1998; 50:A369.
58. Beynon RJ, Bartram C, Hopkins P, Toescu V, Gibson H, Phoenix J, Edwards RHT. McArdle's disease: Molecular genetics and metabolic consequences of the phenotype. Muscle Nerve 1995; (Suppl 3):S18-S22.
59. 6 and aerobic training be the best therapeutic approach while waiting for effective gene therapy?
60. Baque S, Newgard CB, Gerard RG, Guinovart JJ, Gomez-Foix AM. Adeno-virus-mediated delivery into myocytes of muscle glycogen phosphorylase, the enzyme deficient in patients with glycogen-storage disease type V. Biochem J 1994; 304:1009-1014.
61. Swoboda KJ, Specht L, Jones HR, Shapiro F, DiMauro S, Korson M. Infantile phosphofructokinasedeficiency with arthrogryposis: clinical benefit of a ketogenic diet. J Pediatr 1997; 131:932-934.